Experimental drug cocktail targets Hard-to-Treat cancers
NCT ID NCT00878163
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the safest dose and understand side effects. The study involves 55 adults whose cancer has not responded to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Orlando Health Cancer Institute
Orlando, Florida, 32806, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Exercise before and after pancreatic cancer surgery may speed recovery and chemotherapy start
- Could a simple blood test catch pancreatic cancer before It's too late?
- New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
- New drug cocktail aims to shrink pancreatic tumors before surgery